SRNE - Sorrento's COVID-19 rapid antigen test detects Omicron variant

Sorrento Therapeutics (NASDAQ:SRNE) announces that initial testing of COVISTIX on recombinant N proteins demonstrated its ability to detect the Omicron variant, in addition to detecting the original SARS-CoV-2 virus and other major variants of concern (VoCs) such as the delta and delta-plus strains. The COVISTIX detection levels were similar for all variants. In a laboratory setting, Sorrento has also studied the ability of COVISTIX to detect the Omicron variant compared to other Emergency Use Authorization approved COVID-19 virus rapid antigen tests. Initial lab results demonstrate that COVISTIX was able to detect the Omicron N protein at a significantly lower level than other commercially available tests. Sorrento currently has the capacity to produce 30M COVISTIX tests a month and is currently building up its manufacturing capacity in U.S. The company anticipates having a fully automated assembly line capable of producing 6M COVISTIX units per month up and running in Q1 2022. Pending

For further details see:

Sorrento's COVID-19 rapid antigen test detects Omicron variant